ArticleCancer science2017
Expression level of CXCL7 in peripheral blood cells is a potential biomarker for the diagnosis of renal cell carcinoma.
Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway.Cell death & disease · 2025Article
- CSF2 polarized neutrophils and invaded renal cancer cellsOpen medicine (Warsaw, Poland) · 2025Article
- Cytokine profile of cerebrospinal fluid in pediatric patients with metastatic medulloblastoma.Heliyon · 2024Article
- Predictive three-biomarker panel in peripheral blood mononuclear cells for detecting hepatocellular carcinoma.Scientific reports · 2024Article
- Alterations in Gene Pair Correlations as Potential Diagnostic Markers for Colon Cancer.International journal of molecular sciences · 2022Article
- Expression ofTranslational cancer research · 2022Article
- Screening and identification of biomarkers associated with the immune infiltration of intracerebral hemorrhage.Journal of clinical laboratory analysis · 2022Article
- Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.Frontiers in pharmacology · 2022Review
- Review
- FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells.Cancer letters · 2021Article
- Article
- Increased CCL24 and CXCL7 levels in the cerebrospinal fluid of patients with neurosyphilis.Journal of clinical laboratory analysis · 2020Article
- Predicting the Risk of Melanoma Metastasis Using an Immune Risk Score in the Melanoma Cohort.Frontiers in bioengineering and biotechnology · 2020Article
- Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer.Frontiers in oncology · 2020Article
- Expression signatures of long non-coding RNA and mRNA in human traumatic brain injury.Neural regeneration research · 2019Article
- Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer.Frontiers in oncology · 2019Article
- Expression level of CXCL7 in peripheral blood cells is a potential biomarker for the diagnosis of renal cell carcinoma.Cancer science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no blood biomarkers for the diagnosis of renal cell carcinoma (RCC) in routine clinical use. We focused on the gene expression profile of peripheral blood cells obtained from RCC patients to discover novel biomarkers for RCC diagnosis. Using microarray analysis and quantitative verification, CXCL7 was shown to be significantly upregulated in the peripheral blood cells of RCC patients. Importantly, aberrant CXCL7 expression was confirmed even in peripheral blood cells obtained from early stage (pT1a) RCC patients, and the expression level of CXCL7 in peripheral blood cells was a potential independent biomarker for the diagnosis of RCC by receiver operating characteristic curve analysis (sensitivity, 70.0%; specificity, 64.0%; area under the curve = 0.722; multiple logistic regression analysis: odds ratio, 1.07; 95% confidence interval, 1.03-1.11; P = 0.0004). Moreover, CXCL7 expression in peripheral blood cells significantly decreased after resection of the primary tumor. CXCL7 is more highly expressed in PBMCs than in neutrophils from both healthy controls and RCC patients. Interestingly, CXCL7 expression in PBMCs from healthy volunteers was significantly elevated following coculture with RCC cells compared to those cocultured with normal cells as a control. These results suggest that aberrant CXCL7 expression in peripheral blood cells is induced by RCC cells and may serve as a novel biomarker in the diagnosis of RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.